Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE).

Trial Profile

Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE).

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2011

At a glance

  • Drugs Clopidogrel (Primary)
  • Indications Coronary thrombosis; Myocardial ischaemia
  • Focus Pharmacodynamics
  • Acronyms SPACE
  • Most Recent Events

    • 27 Jun 2011 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 27 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top